Loading
Acacia Pharma
Acacia Pharma was a Cambridge company that repurposed the old antipsychotic amisulpride, at low dose, to prevent and treat nausea and vomiting after surgery and chemotherapy; it was bought by Eagle Pharmaceuticals in 2022.
Also called: Acacia Pharma LtdAcacia Pharma Group
Overview
Acacia Pharma, founded in 2007 in Cambridge, England, developed intravenous low-dose amisulpride (Barhemsys) for postoperative nausea and vomiting, approved by the FDA in 2020, and tested the same drug (APD403) in phase 3 for chemotherapy-induced nausea and vomiting. Eagle Pharmaceuticals acquired the company in 2022. Its trials remain on ClinicalTrials.gov under Acacia as lead sponsor.
Connected
5Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyCyclacel Pharmaceuticals
- CompanyVion Pharmaceuticals
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
acaciapharma.com · 1
ClinicalTrials.gov · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/